Trial
NCT03277482
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Dana-Farber Cancer Institute
Collaborators
AstraZeneca
Condition
Recurrent Gynecological Cancer
Intervention
Durvalumab
Why stopped
Expansion cohort was not open
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-31